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Although there are multiple potential collagen-bind-
ing proteins on platelets, the contribution of each to
collagen-induced signaling events and platelet activa-
tion is unclear. We investigated which early platelet
signaling events, if any, could be attributed specifically
to the binding of collagen to one of its receptors, the a2b1
integrin. Treatment of platelets with collagen induced a
rapid activation of the non-receptor tyrosine kinase,
Syk, as measured by an increase in phosphorylation and
kinase activity. Collagen also induced the rapid phos-
phorylation of phospholipase Cg2 (PLCg2). The phos-
phorylation of both Syk and PLCg2, as well as platelet
aggregation, was blocked by an anti-a2b1 integrin mono-
clonal antibody (P1E6), demonstrating that collagen
binding to a2b1 is necessary for signaling. Cross-linking
of the a2b1 integrin with stimulatory monoclonal anti-
body against either the b1 or a2 subunit stimulated the
phosphorylation of both Syk and PLCg2. However, anti-
body stimulation was dependent on co-stimulation of
the FcgII receptor (CD32) since specific F(ab*)2 frag-
ments did not induce Syk and PLCg2 phosphorylation.
Thus, these results suggest that occupancy of a2b1 by
collagen is necessary, but that a co-receptor, in addition
to a2b1, is required for these collagen-induced signaling
events. Moreover, the P1E6 antibody did not inhibit all
collagen-induced tyrosine phosphorylation events, dem-
onstrating that collagen also induces phosphorylation
events that are independent of the a2b1 integrin. In ad-
dition to Syk and PLCg2, we identified the FcgII recep-
tor (FcgRII) as being rapidly phosphorylated in re-
sponse to collagen stimulation, even in the absence of
antibodies. Finally, to determine if Syk activation pre-
cedes and directly contributes to the phosphorylation of
PLCg2, platelets were preincubated with the Syk-selec-
tive kinase inhibitor, piceatannol. A concentration of
piceatannol that inhibited the phosphorylation and ki-
nase activity of Syk, but had no effect on Src kinase
activity, blocked the collagen-induced phosphorylation
of PLCg2 and also inhibited collagen-induced platelet
aggregation. Our results begin to delineate a signaling
pathway whereby occupancy of the a2b1 integrin is re-
quired, but not sufficient, for collagen-induced activa-
tion of Syk and the subsequent phosphorylation of
PLCg2. These events are necessary for platelet activa-
tion and aggregation in response to collagen.
Platelet adhesion to collagen at sites of vascular injury ini-
tiates a cascade of signaling events leading to platelet activa-
tion and aggregation. Several collagen-binding proteins exist
on the platelet surface that may mediate platelet activation by
collagen, including the a2b1 integrin (1, 2), glycoprotein (GP)
1
VI (3), GPIV (also known as GPIIIa or CD36 (4, 5)), and a
65-kDa protein (6, 7). Although multiple potential collagen
receptors exist on platelets, the relative contribution of each in
signaling collagen-induced platelet activation is unknown.
The a2b1 integrin is necessary for the adhesion of platelets to
collagen since patient platelets lacking this integrin do not
adhere to or aggregate in response to soluble collagen fibers (8,
9). Additionally, antibodies against the a2b1 integrin block
platelet aggregation in response to soluble collagen (10) and
adhesion to immobilized collagen (2, 11, 12). A more direct role
for the a2b1 integrin in early collagen-induced platelet signal-
ing events, other than mediating the initial adhesion to colla-
gen, has been assumed (13), but has not yet been clearly es-
tablished. Platelet adhesion to immobilized collagen induces
the phosphorylation of unknown 40-, 101-, and 105-kDa pro-
teins and of pp125FAK (14–16). However, the role of a2b1 in
these events is difficult to establish since anti-a2b1 integrin
antibodies almost totally inhibit adhesion to immobilized col-
lagen (12, 14). Therefore, it is not clear whether blocking the
a2b1 integrin disrupts specific signaling events or simply the
initial adhesion of platelets to collagen.
A direct role for the a2b1 integrin in mediating signal trans-
duction in platelets would be consistent with emerging data
linking integrins to various signaling events (for review, see
Ref. 17). For example, the phosphorylation of numerous pro-
teins during platelet aggregation has been shown to be depend-
ent on the aIIbb3 integrin (18–20), which becomes functionally
active following platelet activation. Recently, Lin et al. (21)
have found that engagement of b1 integrins on monocytes in-
duces Syk activation and NF-kB-dependent gene expression.
Additionally, integrins have been shown to mediate the phos-
phorylation of numerous proteins (22–27), the activation of
mitogen-activated protein kinases (28), the stimulation of met-
alloproteinase gene expression (29), and the activation of the
Na1/H1 antiporter (30). The a2b1 integrin has been implicated
in signaling events in cells other than platelets since it medi-
ates the activation of Ras in T-cells (31), the morphological
organization of mammary cells in three-dimensional collagen
gels (32), and collagenase expression in osteosarcoma cells (33).
However, the mechanism by which the a2b1 integrin or any
other integrin transduces signals in cells is still poorly
understood.
Although the a2b1 integrin is likely to play a role in collagen-
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induced platelet activation, its role is confused by data suggest-
ing that other collagen-binding proteins also contribute to
platelet signaling. For example, it is clear that GPVI plays an
important role in collagen-induced platelet activation since
patient platelets deficient in GPVI are defective in collagen-
induced aggregation and exhibit partially decreased cation-
independent adhesion to collagen (3, 34, 35). GPVI directly
contributes to signaling in the platelet, as shown by the recent
finding that cross-linking of GPVI with antibodies causes the
Fc-independent activation and phosphorylation of the non-re-
ceptor tyrosine kinase, Syk (36). A role for the p65 collagen-
binding protein, which has a similar molecular mass compared
with GPVI, is also suggested since an anti-p65 antibody inhib-
its collagen-induced platelet aggregation (7). A role for GPIV/
CD36 is less clear since platelets from patients lacking GPIV
(the Naka negative phenotype) aggregate and adhere normally
to collagen (37–40). In spite of this finding, GPIV may play
some role since it is physically associated with the Src family
kinases, Fyn, Yes, and Lyn (20). The presence of other collagen
receptors on platelets may explain the finding that triple-heli-
cal collagen-like synthetic peptides are able to stimulate plate-
let aggregation in an a2b1-independent manner (41).
Collagen stimulation of platelets leads to the phosphoryla-
tion of numerous proteins (Refs. 4, 13, 18, and 42; for review,
see Ref. 43). Collagen induces the tyrosine phosphorylation and
activation of phospholipase Cg2 (44, 45), which cleaves phos-
phatidylinositol 4,5-bisphosphate into diacylglycerol and inosi-
tol 1,4,5-trisphosphate. These second messengers, in turn,
cause the activation of protein kinase C and the release of
intracellular calcium, which are necessary for the subsequent
events leading to granule secretion, activation of the aIIbb3
integrin, aggregation, and actin polymerization (46–49). The
72-kDa non-receptor tyrosine kinase, Syk, a member of the
Zap70 kinase family, is also tyrosine-phosphorylated and acti-
vated in platelets following stimulation by collagen (50). Like
collagen, stimulation of platelets through either the FcgII re-
ceptor or CD9 also causes activation of both PLCg2 and Syk
(44, 51–55). Additionally, a number of other agonists (including
thrombin (56) and the thromboxane A2 mimetic, U46619 (57))
also stimulate Syk phosphorylation. The activation of platelets
by thrombin causes the relocation of Syk to the cytoskeletal
fraction (58, 59) and its association with phosphatidylinositol
3-kinase (60), suggesting that Syk has multiple roles in platelet
signaling. Currently, the collagen-induced signaling pathways
in platelets leading to the activation of either PLCg2 or Syk
have not been fully defined.
Because multiple collagen-binding proteins exist on plate-
lets, but the relative contribution of each to collagen-induced
platelet activation has not yet been determined, the purpose of
this study was to determine which intracellular collagen-in-
duced signaling events, if any, could be directly linked to the
function of the a2b1 integrin. Additionally, we sought to deter-
mine whether these signaling events contribute to collagen-
induced platelet aggregation. We find that collagen stimulation
of both Syk and PLCg2 is dependent on the a2b1 integrin.
However, antibody cross-linking of a2b1 is not sufficient to
induce the phosphorylation of Syk and PLCg2 unless the FcgII
receptor is also engaged, suggesting that a2b1 functions in a
co-stimulatory role with other receptors. Moreover, we find
that blocking the a2b1 integrin does not inhibit all collagen-
induced phosphorylation events, which further suggests that
multiple collagen receptors are simultaneously activated dur-
ing platelet binding to collagen. We also identify one additional
phosphorylation event induced by collagen, that of FcgRII,
even in the absence of added antibody. Finally, our data sug-
gest that Syk kinase activity is upstream of PLCg2; these
signaling events had not previously been ordered on the same
pathway in platelets. Moreover, inhibition of Syk activity sup-
presses collagen-induced platelet aggregation, suggesting an
important role for Syk in the activation of platelets.
EXPERIMENTAL PROCEDURES
Materials—Piceatannol was a generous gift of Dr. Robert Geahlen
(Purdue University, West Lafayette, IN). The anti-a2b1 integrin anti-
body JBS2 was a generous gift of Dr. John Wilkins (RDU Research
Laboratory, Winnipeg, Manitoba, Canada). The anti-a2b1 integrin an-
tibody P1H5 was a generous gift of Dr. William Carter (Fred Hutchin-
son Cancer Research Center, Seattle, WA), and P1E6 was purchased
from Life Technologies, Inc. The anti-Src antibody 327 was a generous
gift of Dr. Patricia Maness (University of North Carolina, Chapel Hill,
NC). The polyclonal anti-Syk antibody was a generous gift of Dr. An-
drew Chan (Washington University, St. Louis, MO) and was also pur-
chased, along with PLCg2, from Santa Cruz Biotechnology (Santa Cruz,
CA). The anti-phosphotyrosine antibody PY-20 and the recombinant
RC-20 were purchased from Transduction Labs (Lexington, KY). Sec-
ondary F(ab9)2 anti-mouse IgG and horseradish peroxidase-conjugated
anti-rabbit IgG were purchased from Jackson ImmunoResearch Labo-
ratories, Inc. (West Grove, PA). Hybridomas for the anti-b1 integrin
antibody (TS2/16), anti-FcgRII antibody (IV.3), and isotype-matched
control IgGs were obtained from American Type Culture Collection, and
antibodies were prepared in the monoclonal core facility of the Depart-
ment of Pharmacology (University of North Carolina, Chapel Hill).
Protein G-Sepharose was purchased from Pharmacia (Uppsala). Tubu-
lin was a generous gift of Dr. Michael Caplow (University of North
Carolina, Chapel Hill). Collagen fibers were formed from bovine skin
collagen (type I; Collaborative Biomedical Products, Becton Dickinson,
Bedford, MA) by neutralizing the collagen solution in 10 mM Na2HPO4
to give a final concentration of 2 mg/ml. Prostaglandin E1 and U46619
were obtained from Cayman Chemical Co., Inc. (Ann Arbor, MI). De-
oxycholic acid was from Calbiochem. All other chemicals were from
Sigma unless otherwise noted. Gel electrophoresis and transfers were
performed using a Novex Xcell II system.
Platelet Preparation, Stimulation, and Aggregation—Blood was ob-
tained from healthy consenting human donors using acid-citrate/dex-
trose as an anticoagulant, and platelets were prepared by centrifuga-
tion as described (61). Briefly, platelet-rich plasma was separated from
whole blood at 800 rpm in a Beckman GP tabletop centrifuge for 25 min,
treated with prostaglandin E1 (50 ng/ml), and centrifuged at 1800 rpm
for 20 min to pellet the platelets. Platelets were washed once in citrate/
dextrose/NaCl (pH 7.0) and resuspended in buffer A (12 mM NaHCO3,
138 mM NaCl, 5.5 mM glucose, 2.9 mM KCl, 50 mM HEPES (pH 7.3), 2
mM MgCl2, and 1 mM CaCl2). The platelet concentration was deter-
mined using a Thrombocounter (Coulter Corp., Hialeah, FL). Platelets
were diluted in buffer A to 109/ml and, where indicated, treated with
200 mg/ml bovine skin collagen fibers (Collaborative Research).
Platelet aggregation studies were performed to determine platelet
function for every platelet preparation. Platelets were resuspended in
buffer A at a concentration of 2 3 108/ml, incubated at 37 °C under
stirring conditions in an aggregometer (Chrono-Log Corp., Havertown,
PA), and activated by the addition of collagen (200 mg/ml) or anti-
integrin or control antibodies in the presence or absence of added
fibrinogen. Incubation of isolated platelets in an aggregometer with
added fibrinogen in the absence of agonist demonstrated that the plate-
lets were not pre-activated.
Immunoprecipitation and Immunoblotting—Platelets were lysed by
the addition of an equal volume of ice-cold 2 3 RIPA buffer (50 mM
HEPES (pH 7.3), 150 mM NaCl, 2% Nonidet P-40, 1% deoxycholate,
0.2% SDS, 2 mM sodium vanadate, 100 mM NaF, 20 mM sodium pyro-
phosphate, 10 mg/ml leupeptin, 20 mg/ml aprotinin, 5 mM Pefabloc
(Boehringer Mannheim), 5 mM benzamidine HCl, and 2 mM EDTA) at
4 °C for 30 min, centrifuged at 15,000 3 g for 15 min, and precleared for
1 h by the addition of protein G-Sepharose (GammaBind, Pharmacia).
Cleared lysates were incubated overnight with the polyclonal anti-Syk
or anti-PLCg2 antibody or with the monoclonal antibody IV.3 to immu-
noprecipitate FcgRII plus protein G-Sepharose at 4 °C and then washed
three times with 1 3 RIPA lysis buffer. Immunoprecipitated proteins
were eluted in 1 3 Laemmli sample buffer, reduced, subjected to SDS-
polyacrylamide gel electrophoresis, and transferred to polyvinylidene
difluoride membranes. To determine phosphotyrosine content, mem-
branes were incubated with the anti-phosphotyrosine antibody (PY-20
or RC-20) conjugated to horseradish peroxidase and visualized using
the ECL reagent (Amersham Corp.). To reprobe membranes for PLCg2
or Syk, membranes were incubated overnight with NaN3 in order to
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inhibit horseradish peroxidase activity, washed, and reprobed with the
anti-PLCg2 or anti-Syk antibody, followed by horseradish peroxidase-
conjugated anti-rabbit IgG.
Treatment with Antibodies, Peptides, and Inhibitors—For antibody
inhibition studies, platelets were incubated with the anti-a2 integrin
antibody, P1E6, at a dilution of 1:1000 or isotype-matched IgG or
without antibody for another 3 min, followed by stimulation with or
without collagen for 2.5 min. For antibody stimulation experiments,
platelets were preincubated with rabbit IgG for 3 min in order to block
Fc receptors and incubated with anti-b1 integrin TS2/16 or IgG for 3
min, and where indicated, antibodies were cross-linked with anti-mouse
F(ab9)2 for 5 min. It was later determined that treatment with rabbit
IgG was not sufficient to completely block the Fc receptors (see below).
F(ab9)2 fragments of TS2/16 were prepared by digesting the antibody
with immobilized ficin and removing Fc fragments with a protein A
column (Pierce). Gel electrophoresis confirmed that no contaminating
intact IgG remained. Platelets were then lysed by the addition of 2 3
RIPA buffer as described above. For peptide inhibition studies, the
peptide GPAGKDGEAGA, representing residues 430–440 from the a1
chain of collagen I (62), was synthesized at the University of North
Carolina core protein synthesis facility (UNCCH-NIEHS). The peptide
was diluted in buffer A, and platelets were preincubated with the
indicated concentration of peptide for 5 min, stimulated with collagen,
and then lysed in 2 3 RIPA buffer.
For FcgRII blocking experiments, platelets were preincubated for 5
min with 20 mg/ml IV.3 antibody and then incubated with anti-integrin
antibodies that were biotinylated using the ECL protein biotinylation
module (Amersham Corp.) according to the manufacturer’s instruc-
tions. Biotinylated antibodies were dialyzed against phosphate-buff-
ered saline prior to use. Biotinylated antibodies were cross-linked with
10 mg/ml avidin (Pierce) for 5 min prior to lysing the platelets in 2 3
RIPA buffer.
Kinase Assay—Precleared lysates, prepared as described above, were
immunoprecipitated with the anti-Syk or anti-Src antibody plus protein
G-sepharose for 2 h and then washed three times with 1 3 RIPA buffer
without detergent. Immunoprecipitates were split into two samples:
one for phosphotyrosine determination and one for the kinase assay,
which was resuspended in 20 ml of kinase buffer (25 mM HEPES (pH
7.5), 10 mMMnCl2, and 10 mM p-nitrophenyl phosphate) plus 1 mM ATP,
5 mCi of [g-32P]ATP (Amersham Corp.), and 10 mg of tubulin and
incubated at 24 °C for 2 min. The assay was terminated by adding 3 3
Laemmli sample buffer and boiling the samples for 3 min. Samples
were electrophoresed, and the gels were stained with Coomassie Bril-
liant Blue, dried, and subjected to autoradiography.
RESULTS
Kinetics of the Collagen-induced Phosphorylation of PLCg2
and Syk—Treatment of platelets with collagen (200 mg/ml)
under non-stirring conditions caused the phosphorylation of
Syk on tyrosine within 1 min (Fig. 1). This collagen-induced
phosphorylation persisted for 20 min. Other investigators have
also noted similar kinetics of Syk phosphorylation following
collagen stimulation (48). Stimulation of platelets by thrombin
(Fig. 1) or the thromboxane A2 mimetic, U46619 (data not
shown), also induced the tyrosine phosphorylation of Syk be-
tween 30 s and 2.5 min. Collagen-induced tyrosine phosphoryl-
ation of PLCg2 lagged behind that of Syk since obvious phos-
phorylation did not occur until 2.5 min, with only a faint
phosphorylated PLCg2 band visible at 1 min (Fig. 1). Stimula-
tion of Syk and PLCg2 phosphorylation was independent of
platelet aggregation since it occurred in the absence of stirring
or when aggregation was blocked by the addition of a synthetic
RGDW-containing peptide, which blocks fibrinogen binding to
the aIIbb3 integrin (data not shown). We also observed the
phosphorylation of PLCg2 after treatment with thrombin (Fig.
1) or U46619 (data not shown) for 2.5 min. This result is in
contrast to the results of Daniel et al. (45) or Blake et al. (44),
who did not find PLCg2 phosphorylation following thrombin
treatment, but is consistent with the results of Tate and
Rittenhouse (63).
Tyrosine Phosphorylation of PLCg2 and Syk Is Dependent on
the a2b1 Integrin—To determine the role of the a2b1 integrin in
collagen-induced platelet signaling events, platelets were pre-
treated with an anti-a2b1 integrin mAb (P1E6) that blocks
a2b1-mediated binding of platelets to collagen (11). As shown in
Fig. 2A, P1E6 treatment dramatically decreased the phospho-
rylation of both Syk and PLCg2. In control experiments, an
isotype-matched IgG did not inhibit the phosphorylation of Syk
or PLCg2 (Fig. 2A). Inhibition of Syk and PLCg2 phosphoryl-
ation was confirmed using a different function-blocking anti-a2
integrin antibody (P1H5) (data not shown). These results sug-
gest that collagen interaction with a2b1 is necessary for the
phosphorylation of PLCg2 and Syk.
We also examined the effect of the anti-a2b1 integrin mAb on
the total phosphotyrosine content of collagen-treated platelets.
Antibody blocking of the a2b1 integrin caused the loss of several
phosphotyrosine bands, including a band just larger than 100
kDa. However, not all signaling events were affected since the
collagen-induced tyrosine phosphorylation of several other un-
identified proteins, including at least three major bands at
about 46, 50, and 65 kDa, was not inhibited by the presence of
the anti-a2b1 integrin mAb (Fig. 2B), suggesting that collagen
interacts with the platelet surface even when the a2b1 integrin
has been blocked.
In aggregation assays, the anti-a2b1 integrin mAb (P1E6)
inhibited collagen-induced platelet aggregation, while control
IgG had no effect (Fig. 2C). This inhibition was specific since
P1E6 did not inhibit platelet aggregation stimulated by throm-
bin (data not shown).
As an additional approach to block the a2b1 integrin, we used
a synthetic peptide from the a1(I) collagen chain, GPAGK-
DGEAGA (KDGEA), a putative ligand of a2b1 that blocks the
cation-dependent adhesion of platelets and breast cells to col-
lagen (62). Pretreatment of platelets with a 3 mM concentration
of the KDGEA peptide resulted in the partial inhibition, and
pretreatment with 10 mM resulted in the total inhibition of both
Syk and PLCg2 tyrosine phosphorylation (data not shown). The
concentration of the KDGEA peptide that was necessary for
inhibition is in close agreement with the concentration neces-
sary to inhibit platelet adhesion to collagen, which was partial
at 3 mM and total at 6 mM (62). As noted for treatment with the
anti-a2b1 integrin antibody, pretreatment of platelets with
KDGEA did not inhibit all tyrosine phosphorylation events
(data not shown). Thus, inhibition of Syk and PLCg2 phospho-
rylation with both an a2b1-specific antibody and peptide sug-
gests that occupancy of the a2b1 integrin is required for colla-
gen-induced Syk and PLCg2 phosphorylation.
Antibody Cross-linking of the a2b1 Integrin Results in the
Phosphorylation of Syk and PLCg2 in an Fc Receptor-depend-
ent Manner—To determine whether cross-linking of a2b1 is
sufficient to induce tyrosine phosphorylation of Syk and
PLCg2, platelets were pretreated with either a stimulatory
anti-b1 integrin mAb (TS2/16) or an isotype-matched control
IgG, followed by cross-linking of the primary antibody with a
FIG. 1. Kinetics of collagen-induced Syk and PLCg2 tyrosine
phosphorylation. Platelets (109) were stimulated with collagen (200
mg/ml) or thrombin (0.4 unit/ml) for the indicated length of time and
then lysed by the addition of 2 3 RIPA buffer. Precleared lysates were
immunoprecipitated with anti-Syk or anti-PLCg2 antiserum as indi-
cated, subjected to SDS-polyacrylamide gel electrophoresis, and immu-
noblotted for phosphotyrosine (p-tyr) with horseradish peroxidase-con-
jugated RC-20. Blots were reprobed for Syk (not shown) or PLCg2 to
control for the amount of protein in each lane. Similar kinetics were
determined in three separate experiments.
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secondary anti-mouse F(ab9)2 antibody to cluster the integrin
receptors. Treatment of platelets in suspension with the TS2/16
antibody, but not control IgG, caused the phosphorylation of
both Syk and PLCg2 (Fig. 3A, left panel). Interestingly, cross-
linking TS2/16 with the secondary antibody was not necessary
since TS2/16 alone also induced the phosphorylation of Syk and
PLCg2. However, there was an enhancement following cross-
linking with the secondary antibody (compare lanes 6 second-
ary). These results are consistent with the results of Lin et al.
(21), who found that TS2/16 alone, in the absence of secondary
antibody, could stimulate Syk phosphorylation in a monocytic
cell line.
To determine whether cross-linking of the a2 subunit stim-
ulates signaling in platelets, we used JBS2, an anti-a2 integrin
mAb that stimulates collagen binding and Ras activation in
T-cells (31). Treatment of platelets in suspension with JBS2
stimulated the tyrosine phosphorylation of PLCg2 (Fig. 3A,
right panel). In contrast to the findings with TS2/16, it was
necessary to cross-link the JBS2 antibody in order to induce
PLCg2 phosphorylation. This difference may reflect a differ-
ence in the way that the TS2/16 and JBS2 antibodies bind to
and stimulate the a2 or b1 integrin subunits. It is possible that
the TS2/16 antibody cross-links two integrin heterodimers even
in the absence of the secondary antibody. We also found that
the level of JBS2-induced phosphorylation was less than that
noted when TS2/16 was used. This difference may be due to the
very strong stimulatory activity of the TS2/16 antibody com-
pared with the JBS2 antibody. Furthermore, since platelets
have a5b1 and a6b1, stimulation of these b1 integrins may also
contribute to the stronger signal noted with TS2/16. Our re-
sults with JBS2 demonstrate that specifically cross-linking the
a2b1 integrin with intact mAb induces signaling in platelets.
Although control IgG did not result in the phosphorylation of
Syk or PLCg2, we investigated whether Fc receptors contrib-
uted to signaling following cross-linking with anti-integrin an-
tibodies. F(ab9)2 fragments of the TS2/16 antibody failed to
stimulate the phosphorylation of either Syk or PLCg2 (Fig. 3B),
demonstrating that the Fc portion of the TS2/16 antibody con-
tributes to its activity. To check the activity of the F(ab9)2
fragments, we took advantage of the fact that the TS2/16 an-
tibody enhances binding of the integrin to collagen and thus
enhances platelet aggregation in response to suboptimal colla-
gen concentrations. We found that the F(ab9)2 fragments of
TS2/16 retained this ability (data not shown), indicating that
the failure of F(ab9)2 fragments to stimulate platelets is not due
to a loss of their activity.
To determine more directly whether FcgRII, which is the
only Fc receptor on platelets, contributes to anti-integrin anti-
body signaling, FcgRII was blocked with 20 mg/ml IV.3 anti-
body prior to stimulation with intact antibodies. To avoid using
a secondary antibody to cluster anti-integrin antibodies, which
would stimulate the platelets by also cross-linking the IV.3
antibody, the anti-integrin and control IgG antibodies were
biotinylated and cross-linked using avidin. Pretreatment of
platelets with IV.3 blocked stimulation of Syk and PLCg2 phos-
phorylation by biotinylated TS2/16 (Fig. 3C), once again sug-
gesting a contribution of FcgRII. Similar results were obtained
FIG. 2. An anti-a2b1 integrin-blocking antibody inhibits Syk
and PLCg2 phosphorylation. Platelets were pretreated with the
anti-a2 integrin mAb, P1E6, or isotype-matched control mouse IgG or
with no antibody, followed by treatment with collagen as indicated.
Following lysis in 2 3 RIPA buffer, precleared lysates were immuno-
precipitated with antiserum against Syk or PLCg2 as indicated (A) or
anti-phosphotyrosine (PY-20) (B). Protein blots in both A and B were
probed for phosphotyrosine (p-tyr) with horseradish peroxidase-conju-
gated RC-20. Blots in A were reprobed for Syk or PLCg2 as noted. In C,
platelets were pretreated with the anti-a2 integrin mAb (P1E6) or
control IgG for 3 min and then stimulated with collagen (200 mg/ml)
under stirring conditions in an aggregometer. The experiment shown is
representative of four similar experiments.
FIG. 3. Cross-linking the a2b1 integrin with antibody induces
Syk and PLCg2 phosphorylation in an FcgRII-dependent man-
ner. A, platelets were incubated with a stimulatory anti-b1 integrin
mAb (TS2/16; left panel), a stimulatory anti-a2 subunit mAb (JBS2;
right panel), or an isotype-matched control mouse IgG as indicated.
Following primary antibody treatment, platelets were incubated with
or without a secondary anti-mouse F(ab9)2 antibody in order to further
cross-link receptors as indicated. Precleared lysates from stimulated
platelets were immunoprecipitated with the anti-Syk or anti-PLCg2
antibody as indicated and probed for phosphotyrosine (p-tyr) using
horseradish peroxidase-conjugated RC-20. Syk immunoprecipitation
following cross-linking with JBS2 was not performed. The TS2/16 ex-
periment is one of three such experiments giving similar results. B,
F(ab9)2 fragments fail to induce phosphorylation of Syk and PLCg2.
Platelets were incubated with intact IgG, an F(ab9)2 fragment of TS2/
16, or an isotype-matched control mouse IgG as indicated, followed by
incubation with a secondary antibody. Precleared lysates from stimu-
lated platelets were immunoprecipitated with the anti-Syk or anti-
PLCg2 antibody as indicated and probed for phosphotyrosine. Shown is
one of three similar experiments. C, preblocking FcgRII blocks TS2/16
antibody stimulation. To block Fc receptors, platelets were preincu-
bated with or without 20 mg/ml IV.3 anti-FcgRII mAb for 5 min as
indicated. Platelets were then incubated with 20 mg/ml biotinylated
TS2/16 or control IgG for 3 min, followed by incubation for 5 min with
10 mg/ml avidin in order to cross-link the biotinylated antibodies. Syk
or PLCg2 was immunoprecipitated as described for A and B, and
blots were probed for phosphotyrosine. Shown is one of two such
experiments.
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with biotinylated JBS2 (data not shown). Anti-integrin anti-
body stimulation led not only to the phosphorylation of Syk and
PLCg2, but also to the tyrosine phosphorylation of FcgRII itself
(data not shown). This phosphorylation of FcgRII was also
blocked by the IV.3 antibody. It is unlikely that anti-integrin
antibody signaling is due solely to a nonspecific effect of anti-
body binding to FcgRII since control IgG antibodies consis-
tently failed to activate Syk or PLCg2 phosphorylation. These
results suggest that antibody clustering of the a2b1 integrin
alone is insufficient to induce Syk and PLCg2 phosphorylation
and that FcgRII co-stimulates platelets treated with anti-inte-
grin antibodies. Cross-linking the a2b1 integrin on the platelet
surface was not sufficient to induce aggregation since treat-
ment of platelets with intact TS2/16 or JBS2 antibodies with or
without the secondary antibody did not cause the aggregation
of platelets (data not shown).
Collagen Causes an a2b1-independent Phosphorylation of
FcgRII—Because FcgRII was necessary for anti-a2b1 integrin
antibody-stimulated phosphorylation of Syk and PLCg2, we
determined whether FcgRII was also a target for tyrosine phos-
phorylation following collagen stimulation. Collagen treatment
of platelets induced the phosphorylation of FcgRII within 1 min
(Fig. 4A). This phosphorylation proceeded for at least 5 min
following collagen stimulation. Unlike the collagen-induced
phosphorylation of Syk and PLCg2, the phosphorylation of
FcgRII was not blocked by pretreatment of platelets with the
anti-a2 integrin antibody (P1E6) (Fig. 4B). In fact, the experi-
ment shown in Fig. 4B (third lane)) suggests that P1E6 may
cause a slight stimulation of FcgRII phosphorylation even in
the absence of collagen. Even with this background level of
phosphorylation, there is still a further stimulation of FcgRII
phosphorylation upon collagen addition (Fig. 4B, compare the
third and fourth lanes), indicating that P1E6 does not inhibit
collagen stimulation of FcgRII phosphorylation. Thus, al-
though antibody stimulation of b1 integrins can induce FcgRII
phosphorylation, collagen stimulation of FcgRII phosphoryla-
tion is a2b1 integrin-independent.
Collagen stimulation of FcgRII phosphorylation was not in-
hibited by pretreating the platelets with the blocking IV.3
anti-FcgRII antibody (Fig. 4C). This implies that collagen prob-
ably does not bind directly to the FcgII receptor. Additionally,
this result suggests that collagen stimulation of FcgRII phos-
phorylation does not occur by inducing platelet release of im-
mune complexes that subsequently bind the FcgII receptor, but
more likely by an internal signaling pathway. Pretreatment of
platelets with IV.3 also did not inhibit the collagen-induced
phosphorylation of Syk or PLCg2 (Fig. 4D) or collagen-induced
platelet aggregation (data not shown), suggesting that if
FcgRII plays a role in collagen stimulation of platelets, this role
is not mediated by its ability to bind Fc ligands. Thus, stimu-
lation of Syk and PLCg2 phosphorylation by collagen differs
from stimulation by anti-a2b1 integrin antibodies, which was
blocked by preincubation with the IV.3 antibody. This differ-
ence suggests that stimulation by collagen does not share the
same requirement for FcgRII binding as stimulation by anti-
integrin antibodies. In the case of antibody stimulation, FcgRII
may substitute for a co-receptor that is normally stimulated by
collagen.
Inhibition of Syk Kinase Activity Also Inhibits the Phospho-
rylation of PLCg2—To determine whether Syk is on the same
pathway and upstream of PLCg2, platelets were treated with
the Syk-selective kinase inhibitor, piceatannol (64). Platelets
were pretreated for 10 min with various concentrations of
piceatannol or Me2SO, followed by treatment with collagen for
2.5 min. Syk phosphorylation was dramatically reduced follow-
ing treatment with 10 mg/ml piceatannol and completely elim-
inated following treatment with 30 mg/ml piceatannol (Fig. 5A).
The tyrosine phosphorylation of PLCg2 was closely correlated
with that of Syk since the phosphorylation of PLCg2 was also
decreased following treatment with 10 mg/ml piceatannol and
completely eliminated following treatment with 30 mg/ml
piceatannol (Fig. 5A). This finding is consistent with a model
placing Syk activity upstream of PLCg2. Piceatannol was less
effective in inhibiting the collagen-induced phosphorylation of
FcgRII since treatment with 10 mg/ml piceatannol did not
inhibit, and 30 mg/ml piceatannol only partially inhibited
FcgRII phosphorylation (Fig. 5A, bottom panel). This is consist-
ent with results suggesting that FcgRII is phosphorylated by
Src in platelets (65). Pretreatment of platelets with piceatannol
also inhibited the tyrosine phosphorylation of several other
(but not all) proteins (Fig. 5B), implying that Syk may be
involved in several phosphorylation events in stimulated
platelets.
Syk is known to have autophosphorylating activity, and its
level of tyrosine phosphorylation correlates with its kinase
activity in platelets (58). To verify that piceatannol inhibited
Syk kinase activity as well as the phosphotyrosine content of
Syk, immune complex kinase assays were performed. Pretreat-
ment of platelets with piceatannol inhibited Syk kinase activity
as measured by autophosphorylation and by the phosphoryla-
tion of an exogenous substrate, tubulin (Fig. 5C). Treatment of
platelets with 30 mg/ml piceatannol inhibited Syk kinase activ-
ity by 72% (Table I). In contrast, Src kinase activity was not
significantly affected by pretreatment of platelets with piceat-
annol (Fig. 5C and Table I). Treatment of platelets with 10
mg/ml piceatannol did not significantly inhibit Syk kinase ac-
tivity (Fig. 5C and Table I), even though this concentration
partially inhibited the tyrosine phosphorylation of Syk (Fig.
5A). The reason for this difference is not clear, but may be due
to the removal of piceatannol in washing steps before the ki-
nase assay; kinase activity may therefore appear to be less
sensitive to inhibition by piceatannol than in the direct phos-
photyrosine blots shown in Fig. 5A. Our results are consistent
with those of Oliver et al. (64), who found that pretreatment of
mast cells with 50 mg/ml piceatannol inhibited Syk kinase
FIG. 4. Collagen induces the a2b1-independent phosphoryla-
tion of FcgRII. A, platelets were incubated with 200 mg/ml collagen
and, at the indicated times, lysed by the addition of 2 3 RIPA buffer.
Precleared lysates were immunoprecipitated with the IV.3 anti-FcgRII
mAb or control IgG, subjected to SDS-polyacrylamide gel electrophore-
sis, and immunoblotted for phosphotyrosine with horseradish peroxi-
dase-conjugated RC-20. Similar kinetics were observed on two separate
occasions. B, the anti-a2 integrin mAb (P1E6) does not inhibit collagen-
induced FcgRII phosphorylation. Platelets were pretreated with P1E6
or isotype-matched control mouse IgG as indicated, followed by treat-
ment with collagen for 2.5 min. Lysates were immunoprecipitated with
the IV.3 mAb and probed for phosphotyrosine as described for A. The
blot was reprobed for FcgRII with the IV.3 antibody as indicated. The
experiment shown is representative of three separate experiments. C
and D, pretreatment with the IV.3 antibody does not block the collagen-
induced phosphorylation of FcgRII, Syk, or PLCg2. Platelets were pre-
treated with or without the IV.3 antibody in order to block FcgRII and
then incubated with collagen for 2.5 min as indicated. Lysates were
immunoprecipitated with additional IV.3 antibody (C) or with anti-Syk
or anti-PLCg2 antiserum (D) and probed for phosphotyrosine (p-tyr).
The experiments shown are representative of two similar experiments.
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activity, but not the Src family kinase Lyn. Thus, the concen-
trations of piceatannol used here seem to be relatively specific
for Syk and do not affect Src family kinases, which suggests
that the inhibition of PLCg2 phosphorylation by piceatannol is
due to an effect on Syk activity. However, the possibility still
exists that piceatannol also affects other kinases in platelets
as well.
The effects of piceatannol on platelet aggregation were also
studied. Collagen-induced platelet aggregation was partially
inhibited by pretreatment of platelets with 10 mg/ml piceatan-
nol and totally inhibited by pretreatment with 30 mg/ml piceat-
annol (Fig. 5D). Collagen-induced platelet shape change was
also inhibited by 30 mg/ml piceatannol. Piceatannol also inhib-
ited platelet aggregation in response to thrombin and U46619.
As with collagen-induced aggregation, 10 mg/ml piceatannol
caused a partial inhibition, and 30 mg/ml piceatannol caused a
total inhibition of thrombin-induced aggregation (Fig. 6). Un-
like collagen stimulation, platelets pretreated with 30 mg/ml
piceatannol still exhibited shape change in response to throm-
bin or U46619 (Fig. 6). This suggests that the mechanisms
leading to collagen-induced platelet shape change are different
from those stimulated by G-protein-coupled receptors. The in-
hibition of platelet aggregation by piceatannol suggests an
important role for Syk in platelet activation by a number of
agonists.
DISCUSSION
We have shown that occupancy of the a2b1 integrin is nec-
essary, but not sufficient, for the collagen-induced tyrosine
phosphorylation of Syk and PLCg2 in platelets. Blocking of the
a2b1 integrin using either inhibitory antibodies or a collagen-
derived peptide that is a putative a2b1 ligand inhibited the
phosphorylation of both Syk and PLCg2. Additionally, cross-
linking of the b1 or a2 subunits with stimulatory antibodies in
solution co-stimulated, along with FcgRII, the phosphorylation
of both Syk and PLCg2. These early platelet signaling events
had not previously been linked directly to occupancy of the a2b1
integrin. Furthermore, we find evidence for a possible role for
the FcgII receptor in collagen stimulation since collagen in-
duced the phosphorylation of FcgRII, a finding that, to our
knowledge, had not previously been reported. By using the
Syk-selective inhibitor, piceatannol, we are able to place Syk
activation upstream of PLCg2 in platelets. Our results begin to
define a pathway whereby collagen binding to the a2b1 integrin
contributes to the activation of Syk and the subsequent phos-
phorylation of numerous proteins including PLCg2, leading to
platelet activation and aggregation.
Although Syk activation has been assumed by some investi-
gators to occur upstream of PLCg2, this order of events in
platelets was not previously established. Several pieces of evi-
dence support the positioning of Syk activation upstream of
PLCg2. First, inhibition of Syk by the Syk-selective kinase
inhibitor, piceatannol, inhibited not only Syk kinase activity
and tyrosine phosphorylation, but also PLCg2 phosphorylation.
In our hands, in agreement with Oliver et al. (64), concentra-
tions of piceatannol that inhibited Syk activity had no signifi-
cant effect on Src family kinase activity, suggesting that piceat-
annol specifically inhibits Syk. However, it remains possible
that other kinases are also affected by piceatannol. Second,
kinetic studies demonstrated that Syk phosphorylation oc-
curred before PLCg2 phosphorylation. This agrees with the
observation that, in B-cells, a knockout of the syk gene results
in cells that no longer phosphorylate PLCg2 in response to
B-cell receptor cross-linking (66). It remains to be determined
whether Syk directly phosphorylates PLCg2 or whether there
are other kinases in between Syk and PLCg2.
FIG. 5. Piceatannol inhibits both Syk and PLCg2 phosphoryl-
ation. A and B, platelets were pretreated for 10 min with increasing
concentrations of piceatannol or Me2SO (DMSO) as a control. Platelets
were then stimulated with collagen for 2.5 min and lysed by the addi-
tion of 2 3 RIPA buffer. Precleared lysates were immunoprecipitated
with antibodies against Syk, PLCg2, or FcgRII (A) or with PY-20 to
determine total phosphotyrosine (B) and immunoblotted for phospho-
tyrosine with horseradish peroxidase-conjugated RC-20. Blots in A
were reprobed for Syk or PLCg2 as indicated. Note that 10 mg/ml
piceatannol partially inhibits, and 30 mg/ml piceatannol totally inhibits
both Syk and PLCg2 phosphorylation (A) as well as the phosphorylation
of numerous other proteins (B). 10 mg/ml piceatannol does not inhibit,
and 30 mg/ml piceatannol only partially inhibits FcgRII phosphoryla-
tion (A). These experiments are representative of four such experi-
ments, with consistent sensitivity of phosphorylation to the concentra-
tions shown. C, immune complex kinase assay: platelets were
pretreated with piceatannol or Me2SO, stimulated with collagen for 1
min, and lysed with 2 3 RIPA buffer. Precleared lysates were immu-
noprecipitated for 2 h with antiserum against Syk or mAb 327 against
Src, washed three times in buffer without detergent, and resuspended
in kinase buffer. Phosphorylated proteins were subjected to SDS-poly-
acrylamide gel electrophoresis, and the resulting gels were stained,
dried, and subjected to autoradiography. A quantification of kinase
activity is found in Table I. D, platelets were pretreated for 10 min with
piceatannol or Me2SO as indicated and then stimulated with collagen
under stirring conditions in an aggregometer. This experiment is rep-
resentative of six similar experiments from different donors, all of
which had similar sensitivity to inhibition by piceatannol.
TABLE I






1 mg/ml 101 103
3 mg/ml 82 90
10 mg/ml 76 84
30 mg/ml 28 81
a A quantification of kinase activity was determined by excising the
phosphorylated bands from the dried gel shown in Fig. 5C and counting
them in a scintillation counter. Percent of control is the ratio of the dpm
in the sample treated with piceatannol to the dpm in the Me2SO control
band.
b Syk kinase activity was determined by excising the tubulin band
from the dried gel shown in Fig. 5C.
c Src kinase activity was determined by excising the Src band from
the dried gel shown in Fig. 5C.
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Our data demonstrate that both the a2b1 integrin and the
subsequent activation of Syk and PLCg2 are necessary for
collagen-induced platelet aggregation since either anti-a2b1
integrin antibodies or piceatannol inhibited aggregation. Other
investigators have also noted that collagen-induced platelet
aggregation is inhibited by some anti-a2b1 integrin antibodies
(10) or in platelets missing the a2b1 integrin (2, 8). Although
the a2b1 integrin/Syk pathway was required for collagen-in-
duced platelet aggregation, it was not sufficient since intact
antibody cross-linking of the a2b1 integrin and subsequent Syk
activation did not induce platelet aggregation. This suggests
that multiple signaling events, most likely mediated through
additional collagen-binding proteins, are necessary to cause
full platelet activation. Antibody cross-linking of one putative
collagen-binding protein, GPVI, induces the Fc-independent
activation of Syk and platelet aggregation (36). It is of interest
that both GPVI and the a2b1 integrin seem to be necessary to
elicit the full range of platelet responses to collagen since
patients deficient in either receptor have platelets that are
defective in collagen-induced aggregation (3, 8, 9). The poten-
tial necessity for both receptors to elicit the full range of plate-
let responses to collagen suggests that there may be other
signals independent of the Syk/PLCg2 pathway that contribute
to platelet responses to collagen, some of which are linked to
the a2b1 integrin and some to GPVI, such that eliminating
either receptor might eliminate a portion of the collagen-in-
duced signaling pathway in platelets. Evidence that stimula-
tion of platelets by collagen occurs through two different sites,
both of which are necessary for platelet activation by collagen,
has also been suggested by Santoro et al. (67). It remains to be
determined just how the a2b1 integrin and other collagen re-
ceptors, including GPVI, cooperate in producing the total plate-
let response to collagen.
Our observation that some collagen-induced phosphorylation
events occur even when the a2b1 integrin is blocked by anti-
bodies or peptides suggests, first, that blocking the a2b1 inte-
grin blocks specific signaling events rather than totally inhib-
iting all interactions of platelets with soluble collagen. Second,
this observation suggests that collagen binding to other recep-
tors occurs independent of, and in addition to, collagen binding
to the a2b1 integrin. This finding differs from the observation
that platelets deficient in the a2b1 integrin do not adhere to
collagen (8, 9) and that anti-a2b1 integrin mAbs almost com-
pletely block adhesion to immobilized collagen (11). It is possi-
ble that soluble collagen simultaneously binds the a2b1 inte-
grin and other collagen receptors on platelets, but that the a2b1
integrin is required for stable adhesion to immobilized colla-
gen. The other collagen-binding proteins on platelets may be
too weak or interact too transiently to mediate stable adhesion
to collagen in the absence of the a2b1 integrin, but are probably
necessary to elicit the full range of platelet responses to
collagen.
The notion that the a2b1 integrin works in conjunction with
other receptors is consistent with FcgRII and the a2b1 integrin
acting together in antibody cross-linking experiments. Anti-
integrin antibodies did not induce phosphorylation of Syk and
PLCg2 when the Fc portion of the antibody was removed or
when FcgRII was blocked with the IV.3 antibody. However,
antibody-induced tyrosine phosphorylation was not solely due
to FcgRII since only the anti-b1 integrin antibody, and not
control IgG, caused the phosphorylation of Syk and PLCg2. It is
likely that the anti-integrin antibody caused a clustering of the
integrin with FcgRII. This heterotypic clustering differs from
homotypic clustering of FcgRII alone since anti-integrin anti-
bodies did not induce the platelet aggregation that is observed
upon cross-linking with the anti-FcgRII antibody (65). Func-
tional cooperation between integrins and the FcgII receptor has
also been described for b2 integrins in neutrophils (68, 69).
Our results are not the first in which co-stimulation of
FcgRII contributes to antibody stimulation of platelets. Most
notably, antibodies against the tetraspanin CD9 strongly stim-
ulate platelet aggregation, but only in conjunction with FcgRII
(51, 70). It is thus of interest that CD9 has recently been
co-immunoprecipitated with b1 integrins from various cells (71,
72) and modulates b1 integrin function in B-cells (73). An
interaction between CD9 and the a2b1 integrin was specifically
not found by Berditchevski et al. (72), but remains to be tested
in platelets.
Unexpectedly, collagen stimulation of platelets, in the ab-
sence of antibody, led to the a2b1-independent phosphorylation
of FcgRII. Previously, the tyrosine phosphorylation of an uni-
dentified 40-kDa protein following collagen stimulation had
been reported (15, 16). Our results suggest that this 40-kDa
protein might be FcgRII. Interestingly, this phosphorylation
was not blocked by an anti-a2b1 integrin antibody, suggesting
that the phosphorylation of FcgRII might occur by collagen
binding through a different platelet receptor. This receptor
might be GPVI since anti-GPVI antibodies stimulate the phos-
phorylation of a 40-kDa protein (34). Additionally, collagen-
induced FcgRII phosphorylation was also not blocked by the
IV.3 anti-FcgRII antibody, implying that it did not occur as a
result of binding to an Fc ligand and may, instead, be due to
internal signaling events following collagen stimulation. Colla-
gen is not known to bind FcgRII directly. Although collagen
binding directly to FcgRII is unlikely, if it does occur, it would
have to bind at a site not blocked by IV.3. Our finding differs
from that of Yanaga et al. (55), who observed no phosphoryla-
tion of FcgRII following collagen stimulation. However, their
experiments were performed in the presence of EGTA, which
would affect the divalent cation-dependent functioning of the
a2b1 integrin and possibly other collagen receptors and alter
the overall response of the platelets to collagen.
In spite of these observations, the role of FcgRII in collagen
signaling, if any, is unclear. Blocking FcgRII with the IV.3
antibody had no effect on either collagen-induced FcgRII, Syk,
and PLCg2 phosphorylation or subsequent platelet aggrega-
tion. One possibility is that FcgRII plays no role in collagen-
induced platelet activation, but substitutes for the role of a
co-receptor or co-stimulator in the case of anti-a2b1 integrin
antibody stimulation. In the more physiologic case where a2b1
is bound by collagen, this co-receptor may instead be one of the
other collagen-binding proteins such as GPVI. Alternatively, it
is possible that the presence of phosphorylated FcgRII, in the
absence of Fc ligand binding, is sufficient to contribute to
collagen-induced platelet activation. FcgRII contains a tyro-
sine-based activation motif that, when tyrosine-phosphoryl-
ated, binds and activates Syk in platelets (55, 74), consistent
with the role of tyrosine-based activation motifs in T- and B-cell
FIG. 6. Piceatannol inhibits platelet aggregation induced by
thrombin and U46619. Platelets were pretreated for 10 min with
piceatannol or Me2SO (DMSO) as indicated and then stimulated with
0.4 unit/ml thrombin (A) or 1 mM thromboxane A2 mimetic, U46619 (B),
under stirring conditions in an aggregometer. Shown is one of two such
experiments.
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receptor signaling (75–78). Integrin a and b subunits lack such
a motif, although the b1 subunit does have two tyrosine resi-
dues with similar spacing as those found in tyrosine-based
activation motifs. An attractive model is that FcgRII becomes
phosphorylated as a result of collagen activation and then
serves as a docking molecule to localize Syk to receptor com-
plexes that might include the a2b1 integrin and perhaps other
collagen receptors. Because FcgRII phosphorylation was less
sensitive to inhibition by piceatannol than was Syk or PLCg2
phosphorylation, it is likely that FcgRII is phosphorylated up-
stream of Syk by another kinase. This kinase may be Src since
the phosphorylation of tyrosine-based activation motifs is
thought to occur through the action of Src family kinases (79,
80), which are not inhibited by the concentrations of piceatan-
nol used in our assays (64). Furthermore, Src is implicated as
the kinase that phosphorylates FcgRII following cross-linking
of FcgRII in platelets (65). The determination of whether
FcgRII contributes to collagen activation, or how it does so,
awaits further study.
While other platelet agonists, like collagen, stimulate down-
stream signaling events that include protein kinase C activa-
tion and calcium second messenger signaling, there is evidence
that part of the signaling pathway stimulated by either colla-
gen or the FcgII receptor diverges from that stimulated by
G-protein-coupled agonists such as thrombin or thromboxane
A2. Both collagen- and FcgRII-induced platelet activation are
insensitive to elevated cAMP (15, 48). In contrast, cAMP is a
potent inhibitor of platelet activation induced by thrombin, the
thromboxane mimetic (U46619), or ADP (48). Additionally,
stimulation by collagen or via the FcgII receptor is similarly
sensitive to inhibition by phenylarsine oxide, unlike thrombin
stimulation of platelets (16, 54). Finally, stimulation of Syk
phosphorylation by collagen and via FcgRII is insensitive to the
combined inhibition of protein kinase C and intracellular cal-
cium chelation, also unlike stimulation by thrombin (55).
Some investigators have proposed that the difference be-
tween collagen versus G-protein-coupled receptors could be ex-
plained by the fact that collagen (and FcgRII) activates the
PLCg2 isoform, whereas thrombin activates PLCb. However,
conflicting reports exist as to whether thrombin also stimulates
PLCg2 (44, 45, 63, 65). Our finding that thrombin and U46619
also stimulated PLCg2 phosphorylation is consistent with the
findings of Tate and Rittenhouse (63), but is in contrast to the
findings of Blake et al. (44) and Daniel et al. (45). This may
relate to the fact that these investigators examined PLCg2
phosphorylation only up to 2 min following stimulation by
thrombin or U46619, while in this study, we noted PLCg2
phosphorylation beginning at 2.5 min.
Aggregation studies following treatment of platelets with
piceatannol suggest the general importance of Syk activity to
platelet aggregation. Piceatannol inhibited platelet aggrega-
tion not only in response to collagen, but also in response to
thrombin and U46619. Interestingly, piceatannol completely
inhibited platelet shape change, as determined by aggregation
traces, in response to collagen, but not in response to thrombin
or U46619. These results imply a role for Syk in the initial
collagen-induced shape change, a role that may not be shared
by G-protein-coupled receptors. A role for Syk upstream of
platelet aggregation is further supported by the findings that
Syk activation is rapid (50, 58, 60) and occurs even in the
absence of platelet aggregation and aIIbb3 integrin engagement
(58). Thus, we found that pretreatment of platelets with the
RGDW peptide, which blocks fibrinogen binding to the aIIbb3
integrin, did not inhibit collagen-induced Syk activation. In
spite of our finding that Syk is important to platelet aggrega-
tion, recent studies of Syk null mice demonstrate no obvious
platelet defects (81, 82). Further studies will be needed to fully
determine the role of Syk in platelet aggregation. Additionally,
although Syk activation might be required for platelet aggre-
gation, activation of Syk is not sufficient to cause platelet
aggregation since cross-linking the a2b1 integrin by intact an-
tibodies caused phosphorylation of Syk, but not platelet
aggregation.
A role for Syk in integrin-mediated signaling was also found
by Lin et al. (21) in studies of the a5b1 integrin in the monocytic
cell line THP-1. Thus, Syk activation may be downstream of a
number of integrin receptors in hematopoietic cells. In support
of this, about half of the Syk that becomes activated in aggre-
gating platelets occurs following engagement of the aIIbb3 in-
tegrin during platelet aggregation (58), although Syk is acti-
vated prior to aIIbb3 engagement as well. It will be interesting
to determine whether this represents different subpopulations
or localization of Syk in the platelet.
Activation of focal adhesion kinase differs from Syk since its
activation in stimulated platelets occurs only after platelet
aggregation and requires aIIbb3 integrin engagement (19, 83–
85). Focal adhesion kinase phosphorylation is also known to be
downstream of the a2b1 integrin in the case of platelet adhesion
to immobilized collagen (14). Haimovich et al. (14) also found a
role for the a2b1 integrin in the phosphorylation of two other
unidentified 100- and 105-kDa proteins. In our studies, treat-
ment of platelets with soluble collagen also caused the phos-
phorylation of a similar sized protein (100–110 kDa) that was
inhibited by blocking the a2b1 integrin with antibody. Addi-
tionally, treatment of platelets with piceatannol also caused
the loss of a 100–110-kDa phosphorylated band. The identity of
this protein and whether it is the same as that noted previously
(14) are not known.
In summary, we have elucidated some steps of a2b1 integrin
signaling in platelets by linking specific events to the receptor.
It will be of future interest to determine the proximal signaling
events that lead to Syk activation and how these steps are
regulated by the a2b1 integrin. Additionally, it will be of inter-
est to identify the signaling events unrelated to Syk that may
also have a role in collagen-induced aggregation. Finally, it will
be important to determine how other collagen-binding proteins
contribute to the overall response of platelets to collagen.
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Note Added in Proof—The recent finding by Gibbins et al. that
collagen induces the phosphorylation of the Fc receptor g-chain in
platelets suggests that the Fc receptor g-chain, in addition to or instead
of FcgRII, may play a role as a docking molecule for Syk following
collagen stimulation of platelets. Interestingly, although they do not
make the point, their results are like ours in that they also demonstrate
a tyrosine-phosphorylated band of an appropriate molecular weight to
be FcgRII following collagen stimulation.
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